A 60-Year-Old Woman with Atrial Fibrillation

JAMA

Volumn 290, Issue 16, 2003, Pages 2182-2189

  Singer, Daniel E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; FLECAINIDE; LEVOTHYROXINE; METOPROLOL; WARFARIN; ANTIHYPERTENSIVE AGENT; FIBRINOLYTIC AGENT; THYROXINE;

ADULT; ANTICOAGULATION; BLEEDING; CARDIOVERSION; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE COURSE; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPOTHYROIDISM; LABORATORY TEST; PATIENT SELECTION; PHYSICAL EXAMINATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; ST SEGMENT; THROMBOEMBOLISM; ARTICLE; CLINICAL OBSERVATION; CLINICAL STUDY; DECISION MAKING; DIAGNOSIS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; DECISION MAKING; ELECTRIC COUNTERSHOCK; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; MIDDLE AGED; RISK ASSESSMENT; THYROXINE;

EID: 0142055930     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.16.2182     Document Type: Conference Paper

References (71)

1. Josephson ME, Buxton AE, Marchlinski FE. The tachyarrhythmias. In: Isselbacher K, Braunwald E, Wilson J, Martin J, Fauci A, Kasper D, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill; 1994:1022-1023.
2. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999;82:547-554.
3. Go AS, Hylek EM, Phillips JA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
4. Page RL, Tilsch TW, Connolly SJ, et al. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141-1145.
5. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89:224-227.
6. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271:840-844.
7. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation: the Framingham Heart Study. Circulation. 1994;89:724-730.
8. Waldo AL. Animal models of atrial fibrillation. In: DiMarco J, Prystowsky E, eds. Atrial Arrhythmias: State of the Art. Armonk, NY: Futura Publishing Co; 1995:213-240.
9. Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med. 1997;336:905-911.
10. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med. 1997;336:1429-1434.
11. Sandler G, Wilson GM. The nature and prognosis of heart disease in thyrotoxicosis: a review of 150 patients treated with 1-131. QJM. 1959;52:347-369.
12. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. 2001;104:2118-2150.
13. Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France. Circulation. 1999;99:3028-3035.
14. Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG, for the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Am J Cardiol. 1995;76:355-358.
15. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-934.
16. Al-Khatib SA, Wilkinson WE, Sanders LL, McCarthy EA, Pritchett ELC. Observations on the transition from intermittent to permanent atrial fibrillation. Am Heart J. 2000;140:142-145.
17. Chevalier H. Spontaneous resumption of sinus rhythm in an elderly patient after 13 years of permanent atrial fibrillation. Am Heart J. 1979;98:361-365.
18. Epstein AE, Vidaillet H, Greene HL, et al. Frequency of symptomatic atrial fibrillation in patients enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. J Cardiovasc Electrophysiol. 2002;13:667-671.
19. Evans W, Swann P. Lone auricular fibrillation. Br Heart J. 1953;16:189-194.
20. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987;317:669-674.
21. Go AS, Hylek EM, Phillips KA, et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation;: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation. 2000;102:11-13.
22. Go AS, Hylek EM, Phillips KA, et al. Effectiveness and safety of warfarin to prevent thromboembolism among 13 559 patients with atrial fibrillation: how well do results of randomized trials apply to clinical practice? the ATRIA Study [abstract]. Circulation. 2002;106(suppl):11-515.
23. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Heart Study. Arch Intern Med. 1987;147:1561-1564.
24. Manning WJ, Silverman DI, Waksmonski CA, et al. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recongnized atrial fibrillation. Arch Intern Med. 1995;155:2193-2197.
25. Manning WJ, Silverman DI. Atrial anatomy and function postcardioversion: insights from transthoracic and transesophageal echocardiography. Prog Cardiovasc Dis. 1996;39:33-46.
26. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG, for the Stroke Prevention in Atrial Fibrillation III Investigators. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1998;31:1622-1626.
27. Stollberger C, Chnupa P, Kronik G, et al, for the ELAT Study Group. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med. 1998;128:630-638.
28. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
29. Benjamin EJ, Wolf PA, RB DA, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
30. Longstreth WT, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5888 participants in the Cardiovascular Health Study. Neurology. 2001;56:368-375.
31. Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med. 1989;19:321-326.
32. Umana E, Solares A, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med. 2003;114:51-55.
33. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
34. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
35. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med. 1997;157:1237-1240.
36. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448.
37. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
38. Hylek EM, Skates SJ, Sheehan MA, Singer DE An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
39. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
40. Hylek EM, Go AS, Chang y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026.
41. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(1 suppl):194S-206S.
42. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5:147-157.
43. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation. Arch Intern Med. 1998;158:1316-1320.
44. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke, 1999;30:1223-1229.
45. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119(suppl):220S-227S.
46. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049-1056.
47. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL, Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183-187.
48. Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc. 1997;45:1060-1065.
49. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
50. Man-Son-Hing M, Laupacis A, O'Connor A, et al. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med. 1996;156:1841-1848.
51. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH, for the Anticoagulation Guidelines Task Force. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother. 1997;31:604-615.
52. Ansell JE. Point-of-care testing: patient self-testing and patient self-management. In: Managing Oral Anticoagulation Therapy Clinical and Operational Guidelines. 2nd ed. New York, NY: Aspen Publishers; 2003:chap 44.
53. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoaguation: a randomized controlled trial. JAMA. 1999;281:145-150.
54. Falk RH. Atrial fibrillation. N Engl J Med. 2001;344:1067-1078.
55. Bjerkelund C, Orning O. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208-216.
56. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-1420.
57. Cox JL. Atrial transport function after the Maze procedure for atrial fibrillation: a 10-year clinical experience. Am Heart J. 1998;136:934-936.
58. Cox JL, Ad N, Palazzo T. Impact of Maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg. 1999;118:833-840.
59. Williams MR, Argenziano M, Oz MC. Microwave ablation for surgical treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg. 2002;14:232-237.
60. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659-666.
61. Saksena S, Prakash A, Ziegler P, et al. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol. 2002;40:1140-1150.
62. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med. 2002;137:648-655.
63. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-759.
64. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002;105:1887-1889.
65. Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly: implications and generalizability of randomized trials. JAMA. 1994;272:1932-1938.
66. Man-Son-Hing M, Laupacis A, O'Connor AM, Coyle D, Berquist R, McAlister F. Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique. Med Decis Making. 2000;20:394-403.
67. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
68. Ricard P, Levy S, Trigano J, et al. Prospective assessment of the minimum energy needed for electrical cardioversion of atrial fibrillation. Am J Cardiol. 1997;79:815-816.
69. Wijffels MC, Kirchhof CJ, Dorland R, Alessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
70. Centers for Disease Control and Prevention. Public health and aging: atrial fibrillation as a contributing cause of death and Medicare hospitalization - United States, 1999. MMWR Morb Mortal Wkly Rep. 2003;52:128-131.
71. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med. 1998;128:639-647.